WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...
Please provide your email address to receive an email when new articles are posted on . Maintenance and reliever therapy using inhaled corticosteroids and formoterol was associated with lower risk for ...
FDA considers this risk to be a class effect of all LABAs, including formoterol, one of the components of SYMBICORT. Currently available data are inadequate to determine whether concurrent use of ...
Among patients with mild asthma, as-needed use of a fixed-dose inhaler combining budesonide and formoterol (Symbicort) proved effective for preventing exacerbations and loss of lung function, but the ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...
The FDA has removed a boxed warning on medicines delivering a combinations of inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) drugs. The FDA has removed a boxed warning of asthma ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback